S&P Futures
4,263.50 -1.25 (-0.03%) Dow Futures
33,193.00 -8.00 (-0.02%) Nasdaq Futures
14,714.75 +0.25 (+0.00%) Russell 2000 Futures
1,741.20 -0.70 (-0.04%) Crude Oil
89.51 +0.28 (+0.31%) Gold
1,840.40 -1.10 (-0.06%)
Devyser Diagnostics AB (publ) (DVYSR.ST)
Chart Events
Performance Outlook
| Previous Close | 65.40 |
| Open | 65.60 |
| Bid | 64.00 x N/A |
| Ask | 65.40 x N/A |
| Day's Range | 65.40 - 67.00 |
| 52 Week Range | 58.60 - 97.20 |
| Volume | |
| Avg. Volume | 6,811 |
| Market Cap | 1.102B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.60 |
| Earnings Date | Nov 09, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 117.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DVYSR.ST
Related Research
PR NewswireDevyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser's unique assays in its CLIA-certified laboratory.
PR NewswireDevyser Diagnostics AB publishes quarterly report for the period April to June 2023
"The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution agreement with US-based Thermo Fisher Scientific. Two new oncology products and one new transplant product were launched during the quarter. Our CLIA-certified laboratory in Atlanta was inaugurated and the first patient test was carried out in this laboratory.", Fredrik Alpsten, CEO, Devyser.
PR NewswireDevyser's NGS products for monitoring of kidney and stem cell transplanted patients receive IVDR approvals
Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe. These tests are the first post-transplant monitoring NGS products to be approved under the new, more comprehensive regulation that came into force in May 2022 and confirm Devyser's two NGS products meet the established safety, efficacy, and quality requirements.
